GPR30 predicts poor survival for ovarian cancer
- 1 September 2009
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 114 (3), 465-471
- https://doi.org/10.1016/j.ygyno.2009.05.015
Abstract
No abstract availableKeywords
This publication has 59 references indexed in Scilit:
- In vivo effects of a GPR30 antagonistNature Chemical Biology, 2009
- Retracted: G-Protein–Coupled Receptor 30 and Estrogen Receptor-α Are Involved in the Proliferative Effects Induced by Atrazine in Ovarian Cancer CellsEnvironmental Health Perspectives, 2008
- Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneumGynecologic Oncology, 2008
- Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC)Endocrine-Related Cancer, 2008
- Pathogenesis of Ovarian CancerInternational Journal of Gynecological Pathology, 2008
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort studyBMJ, 2007
- G Protein–Coupled Receptor 30 (GPR30) Mediates Gene Expression Changes and Growth Response to 17β-Estradiol and Selective GPR30 Ligand G-1 in Ovarian Cancer CellsCancer Research, 2007
- Dietary Risk Factors for Ovarian Cancer: The Adventist Health Study (United States)Cancer Causes & Control, 2006
- Hormone replacement therapy and cancerGynecological Endocrinology, 2001